Close

Business & Industry

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been signed between Shilpa Medicare Limited and Switzerland-based NXI Therapeutics AG, extending the Indian pharmaceutical company’s role in global biologics and specialty therapeutics manufacturing. The agreement covers comprehensive chemistry, manufacturing and...

Novartis Expands Radioligand Therapy Manufacturing in US

Swiss pharmaceutical company Novartis has started construction of a new manufacturing facility in Denton, Texas, as part of its previously announced $23 billion investment plan aimed at expanding research and production operations across the United States. The project, expected...

Angelini Pharma Expands US Presence with Catalyst Pharmaceuticals Acquisition

Angelini Pharma has finalized a definitive agreement to acquire Catalyst Pharmaceuticals for an equity value of approximately €3.5bn ($4.1bn). This move marks a strategic entry into the US market for the company, further consolidating its operational focus on brain...

AddParts Secures Funding for Pharma Manufacturing Resilience

AddParts, a UK-based technology company focused on improving operational continuity in pharmaceutical production environments, has secured a six-figure pre-seed investment from SFC Capital to support the expansion of its virtual storeroom technology. Announced on 29 April 2026 in Sheffield,...

UCB Acquires Candid Therapeutics in a $2 Billion-Plus Deal to Strengthen Immunology Pipeline

Belgian pharmaceutical company UCB is making a substantial move to expand its immunology pipeline, entering into a multi-billion dollar agreement to acquire Candid Therapeutics a clinical-stage biotechnology company working on therapies designed to treat autoimmune disorders by resetting the...

BeOne Signs $2B Trispecific Antibody Deal with Huahui Health

BeOne Medicines has entered into a high-value agreement with Huahui Health, committing $20 million upfront to secure an exclusive option for a preclinical trispecific antibody candidate developed by the Chinese biotech firm. The asset, identified as HH160, targets PD-1,...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a new regulatory initiative to enable real-time clinical trials, marking a structural shift in how drug development data is reviewed. The program, already supported by AstraZeneca and Amgen, introduces a model...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »